美国疾病预防控制中心/美国国立卫生研究院研讨会。结核病生物标志物和替代终点研究路线图。
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
机构信息
Division of Pulmonary and Critical Care, Curry International Tuberculosis Center, San Francisco General Hospital, University of California-San Francisco, CA 94110, USA.
出版信息
Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS.
Abstract
The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation ofa specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.
摘要
美国疾病控制与预防中心和美国国立卫生研究院召集了一次多学科会议，讨论结核病治疗反应的替代标志物。会议的目标是评估最近的替代标志物研究，并为以下方面提供具体建议：(1) 治疗结果生物标志物的资格和验证；(2) 未来临床试验标本和数据采集的标准化，包括最小样本集和采集时间点；(3) 创建一个标本库，以支持生物标志物检测。本文总结了这些建议，并提供了实施这些建议的路线图。
相似文献
1
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.美国疾病预防控制中心/美国国立卫生研究院研讨会。结核病生物标志物和替代终点研究路线图。
Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS.
2
RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration.国际研究项目报告：通过全球合作推进结核病生物标志物研究。
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S155-9. doi: 10.1093/cid/civ611.
3
Biomarkers and surrogate end points in clinical trials of tuberculosis treatment.
J Infect Dis. 2007 Aug 15;196(4):648-9; author reply 649-50. doi: 10.1086/519744.
4
Biospecimen Qualification in a Clinical Biobank of Urological Diseases.泌尿系统疾病临床生物库的生物标本资格认定。
Biopreserv Biobank. 2024 Jun;22(3):257-267. doi: 10.1089/bio.2022.0190. Epub 2023 Oct 25.
5
A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.解决儿童结核病生物标志物开发研究空白的蓝图。
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S164-72. doi: 10.1093/cid/civ613.
6
Biomarkers of tuberculosis: a research roadmap.结核标志物：研究路线图。
Biomark Med. 2013 Jun;7(3):349-62. doi: 10.2217/bmm.13.53.
7
Tuberculosis biomarkers discovery: developments, needs, and challenges.结核病生物标志物的发现：进展、需求和挑战。
Lancet Infect Dis. 2013 Apr;13(4):362-72. doi: 10.1016/S1473-3099(13)70034-3. Epub 2013 Mar 24.
8
Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.下一代 DILI 生物标志物：药物开发中生物标志物的鉴定优先级和生物样本采集的最佳实践。
Clin Pharmacol Ther. 2020 Feb;107(2):333-346. doi: 10.1002/cpt.1571. Epub 2019 Sep 14.
9
Biomarkers of treatment response in clinical trials of novel antituberculosis agents.新型抗结核药物临床试验中治疗反应的生物标志物
Lancet Infect Dis. 2007 Jul;7(7):481-90. doi: 10.1016/S1473-3099(07)70112-3.
10
The quest for biomarkers in tuberculosis.结核病生物标志物的研究
Drug Discov Today. 2010 Feb;15(3-4):148-57. doi: 10.1016/j.drudis.2009.10.005. Epub 2009 Oct 23.
引用本文的文献
1
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.一种用于预测肺结核患者长期治疗结局的药物代谢动力学多状态模型。
J Antimicrob Chemother. 2024 Oct 1;79(10):2561-2569. doi: 10.1093/jac/dkae256.
2
Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia.与中重度临床结核病或贫血的肺结核患者疾病严重程度相关的炎症免疫特征。
Front Immunol. 2023 Dec 12;14:1296501. doi: 10.3389/fimmu.2023.1296501. eCollection 2023.
3
Discovery of Novel Transketolase Epitopes and the Development of IgG-Based Tuberculosis Serodiagnostics.新型转酮醇酶表位的发现和基于 IgG 的结核病血清学诊断的开发。
Microbiol Spectr. 2023 Feb 14;11(1):e0337722. doi: 10.1128/spectrum.03377-22. Epub 2023 Jan 18.
4
Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.标准化 RS 比值指标评估结核病抗微生物疗效和效力。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0148322. doi: 10.1128/aac.01483-22. Epub 2023 Jan 9.
5
Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden.痰核糖体 RNA 合成率的可重复性及其与结核分枝杆菌负荷标志物的关系。
Microbiol Spectr. 2021 Oct 31;9(2):e0048121. doi: 10.1128/Spectrum.00481-21. Epub 2021 Sep 8.
6
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.结核分枝杆菌前体 rRNA 作为衡量药物和方案缩短治疗时间的活性指标。
Nat Commun. 2021 May 18;12(1):2899. doi: 10.1038/s41467-021-22833-6.
7
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.利福喷汀高剂量联合或不联合莫西沙星治疗肺结核缩短疗程的研究：TBTC 研究 31/ACTG A5349 期 3 临床试验方案。
Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22.
8
Gene expression profiles classifying clinical stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-positive cohorts.基因表达谱分类鉴定结核临床分期和监测埃塞俄比亚 HIV 阴性和 HIV 阳性队列的治疗反应。
PLoS One. 2019 Dec 10;14(12):e0226137. doi: 10.1371/journal.pone.0226137. eCollection 2019.
9
The serum concentration of vitamin B as a biomarker of therapeutic response in tuberculosis patients with and without human immunodeficiency virus (HIV) infection.维生素B的血清浓度作为有和无人免疫缺陷病毒（HIV）感染的结核病患者治疗反应生物标志物的研究。
Int J Gen Med. 2019 Sep 20;12:353-361. doi: 10.2147/IJGM.S218799. eCollection 2019.
10
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.新结核病治疗方案的研发：协调临床试验设计、产品注册要求和公共卫生指南。
PLoS Med. 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep.
本文引用的文献
1
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.液体培养基中转阳时间的地域差异：结核病临床试验联盟研究 28 号。非洲的培养转阳时间延迟。
PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358.
2
Immunological biomarkers of tuberculosis.结核的免疫学生物标志物。
Nat Rev Immunol. 2011 May;11(5):343-54. doi: 10.1038/nri2960. Epub 2011 Apr 8.
3
Global tuberculosis drug development pipeline: the need and the reality.全球结核病药物研发管线：需求与现实。
Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9. Epub 2010 May 18.
4
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.结核病的生物标志物和诊断：进展、需求及转化为实践。
Lancet. 2010 May 29;375(9729):1920-37. doi: 10.1016/S0140-6736(10)60359-5. Epub 2010 May 18.
5
Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity.抗结核药物的早期临床开发：科学、统计学和杀菌活性。
Tuberculosis (Edinb). 2010 May;90(3):171-6. doi: 10.1016/j.tube.2010.03.007. Epub 2010 Apr 10.
6
Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.尿液脂阿拉伯甘露聚糖检测在抗逆转录病毒治疗前筛查结核病的诊断效果及其与免疫重建疾病的关系。
AIDS. 2009 Sep 10;23(14):1875-80. doi: 10.1097/qad.0b013e32832e05c8.
7
Timing of relapse in short-course chemotherapy trials for tuberculosis.短程化疗治疗肺结核试验中的复发时间。
Int J Tuberc Lung Dis. 2010 Feb;14(2):241-2.
8
Biomarkers of disease activity, cure, and relapse in tuberculosis.结核病疾病活动、治愈和复发的生物标志物。
Clin Chest Med. 2009 Dec;30(4):783-96, x. doi: 10.1016/j.ccm.2009.08.008.
9
Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods.通过核酸扩增方法检测尿液中的分枝杆菌DNA对结核病进行快速诊断。
Lancet Infect Dis. 2009 Aug;9(8):505-11. doi: 10.1016/S1473-3099(09)70149-5.
10
Biomarkers for tuberculosis disease activity, cure, and relapse.用于结核病疾病活动、治愈和复发的生物标志物。
Lancet Infect Dis. 2009 Mar;9(3):162-72. doi: 10.1016/S1473-3099(09)70042-8.
Zotero 插件